Be The Investor ResearchBD or Boston Scientific? The Cheaper Multiple Does Not Settle the Choice
Boston Scientific still leads BD on growth and operating margin, but it has cut its outlook and faces disruption risk, while BD offers income and steadier guidance.
Boston Scientific screens as the faster-growing medical-device company, while Becton Dickinson offers a dividend and a less demanding sales multiple. The choice is not as simple as buying the lower earnings multiple.
The original comparison put Boston Scientific at roughly 18 times earnings and BD near 56 times, but that gap is distorted by BD's unusually thin trailing net income. On sales, the relationship reverses: BD traded near 2.3 times revenue, compared with about 3.2 times for Boston Scientific. Investors should therefore avoid treating one valuation ratio as a verdict.
Operating performance favors Boston Scientific. Its trailing operating margin was about 21%, versus 14.4% for BD, and its recent revenue growth has been much faster. The company benefits from cardiology franchises including WATCHMAN and electrophysiology products. Those same businesses now create concentration risk. Boston Scientific reduced its 2026 growth outlook after WATCHMAN slowed and competitors took share in U.S. electrophysiology.
The source article also described a September cyberattack as affecting Boston Scientific's manufacturing and shipments. That claim requires caution because it was not confirmed in the official second-quarter materials accessed for this review. It should not be treated as established in the investment case without a company filing or release.
BD's trajectory is slower but more stable. In August it raised the midpoint of adjusted earnings guidance and said revenue growth should finish toward the high end of its low-single-digit range. Management also expects low-single-digit growth in fiscal 2027, with the Alaris infusion-system cycle creating an estimated 200-basis-point drag.
Balance-sheet comparisons also need context. Boston Scientific's debt was smaller relative to market value, while BD reported net leverage near 2.9 times and retained a long-term target of 2.5 times. BD received a $4 billion cash distribution connected with its Biosciences and Diagnostic Solutions transaction and used proceeds for share repurchases and debt reduction, changing the capital structure during the period.
Income investors get another clear distinction: BD yields about 2.2%, while Boston Scientific pays no dividend. That cash return does not offset weak execution, but it changes the total-return profile.
Boston Scientific is the stronger growth business if WATCHMAN and electrophysiology stabilize. BD is the more defensive choice if management can convert modest sales growth into higher margins while reducing leverage. The next reports should be judged on those specific tests, not on a single headline multiple.